Skip to content

Post Operative Delirium Study

Intranasal Insulin and Neurocognitive Function

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04635774
Acronym
PODS
Enrollment
0
Registered
2020-11-19
Start date
2021-02-25
Completion date
2023-11-14
Last updated
2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Keywords

Insulin

Brief summary

Post-operative delirium happens when patients wake up from anesthesia. Patients experiencing post-operative delirium are very confused, not being able to think or function normally. These patients are hard to take care of and they tend to have more dementia as they age compared to patients who don't experience post-operative delirium. Intranasal insulin has been shown to reverse confusion associated with Alzheimer's disease (humans) and AIDS (mice). Intranasal insulin has been safely administered to 1092 patients in 38 different studies. There were no cases of clinically low blood sugar and a few cases of mild nasal irritation that happened also with salt water when the subjects received multiple intranasal doses. No one has tried to reverse post-operative delirium with intranasal insulin. The delirium associated with Alzheimer's Disease and AIDS have very similar symptoms and what happens in the brain is very similar also. The investigators intent is to administer intranasal insulin to patients exhibiting post-operative delirium in order to reverse the symptoms because the investigators think that the three disease states are closely related and intranasal insulin has had some success in reversing the delirium in the other two disease states.

Interventions

DRUGInsulin

40 IU via four activations of an intranasal spray

DRUGSaline

Four activations of an intranasal spray containing placebo (normal saline).

Sponsors

University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

The investigational pharmacist will use randomization software to randomize numbers 1-30. Each number will be randomized to either active drug (regular insulin) or placebo (normal saline).The investigational pharmacist will have the randomization table should un-blinding be required.

Intervention model description

The study is double-blind, randomized, placebo controlled. Neither the physician, patient, nor investigator will be aware of which patient is receiving insulin and which is receiving placebo. The treatment group will receive 40 IU via four activations of an intranasal spray. The placebo group will receive four activations of an intranasal spray containing placebo (normal saline). Both groups of patients receiving the insulin or placebo as intervention will be assessed with the CAM assessment at 10 min, 30min, and 60 min, and 6hr.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients (\>65 years of age) undergoing elective surgery using vapor anesthesia displaying post-operative delirium as defined by a CAM evaluation within time to PACU discharge post-surgery are eligible. * Those patients 65 and older undergoing surgery using vapor anesthesia, who are consented but do not exhibit delirium and are not part of the study are still considered recruited subjects, but are not in the active study.

Exclusion criteria

* Patients with a history of severe dementia, anoxic brain injury, or neuromuscular disorders * Non-English-speaking patients * Planned use of drugs that effect plasma glucose concentration during the first four hours of surgery * thiazolidinediones * hormones which may affect plasma glucose or insulin * contraceptive, diphenylhydantoin * patients with allergy to insulin * acromegaly * Cushing's syndrome * hyperthyroidism and pheochromocytoma * renal impairment * pregnant and lactating women * base line blood glucose \< 3.9 mmol/L

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of intranasal insulin in resolving post-operative delirium10 min post diagnosisMeasured by administering the Confusion Assessment Method (CAM) tool

Secondary

MeasureTime frame
Length of stay in the post-anesthesia care unit (PACU)Time from admission to the PACU until discharge from PACU, up to 18 hours from admission to the PACU

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026